

# WHO Drug Information

---

## Contents

### General Policy Issues

Access to essential drugs	217
WHO's role in ensuring access to essential drugs	217
Access to medicines: an urgent need for solutions	220
Amsterdam statement on access to medicines	223

### Reports on Individual Drugs

Influenza preparedness plan: antiviral drugs	225
Atovaquone and proguanil hydrochloride: a new antimalarial combination	226

### Current Topics

Roll Back Malaria	228
The Medicines for Malaria Venture (MMV)	228
The Japanese alliance	228
A new antimalarial donation programme	229
Roll Back Malaria in Europe	229
The WHO Antimicrobial Resistance Information Bank	230

### Vaccines and Biomedicines

Quality assurance and safety of biologicals	231
Influenza preparedness plan: vaccine production and availability	235
Thiomersal: theoretical risk leads to phasing out	237

### Regulatory and Safety Matters

Leflunomide: pancytopenia and skin reactions	238
Didanosine and pancreatitis	238
Sertraline for post-traumatic stress disorder	238
Pemoline withdrawal following liver complications	238
Levetiracetam: new drug for epilepsy	239
Methotrexate: monitoring essential	239
Methotrexate: care in prescribing	239
Grepafloxacin withdrawal: severe cardiovascular events	239
Reteplase incompatible with heparin	239
Postmarketing system to be revised	240
Abacavir: hypersensitivity reactions	240
Initiative to curb illegal sale of drugs over the Internet	240
Unapproved HIV test kits available on the Internet	240
V-King®: unapproved use of sildenafil	241
Miralex®: undeclared corticosteroid	241
Rules for dietary supplements finalized	241

### ATC/DDD Classification

Temporary list	242
Final list	245

### Essential Drugs

WHO Model List (revised December 1999)	249
--	-----

### Proposed International

<b>Nonproprietary Names: List 82</b>	263
--------------------------------------	-----

---